
Bristol Myers Squibb (BMY) Stock
Large pharmaceutical company selling cancer and immune drugs. Here's the price, business snapshot, and what's worth knowing about Bristol Myers Squibb in November 2026.
Bristol-Myers Squibb (BMY) is a large, diversified biopharmaceutical company with a market cap of about $90.7bn. Investors should know it combines an established portfolio of marketed medicines—particularly in oncology, haematology and immunology—with a deep pipeline and substantial R&D spending. Key revenue drivers include immuno‑oncology and speciality medicines, though some legacy products face generic competition as patents expire. The 2019 Celgene acquisition broadened product mix but increased leverage, making cash generation and debt management important considerations. Regulatory outcomes, trial results and competitive approvals can move the share price materially. BMY typically pays a dividend, which may appeal to income‑minded investors, but dividends and share values can fall. This summary is for educational purposes only and not personalised advice; always consider your risk tolerance and do further research or speak to a financial adviser before investing.
Why It’s Moving

Bristol Myers Squibb Shares Face Scrutiny as Analysts Weigh KarXT Trial Success Against Competitive Pressures
- Preliminary Phase 3 data from the ADEPT program shows that KarXT reduced hallucinations and delusions in patients with psychosis associated with Alzheimer's disease, marking a significant clinical milestone for the pipeline.
- The company reported that growth portfolio revenue rose 12% year over year to $7.7 billion, with eight medicines now annualizing over $1 billion each, demonstrating resilience despite patent expiration headwinds.
- Strategic shifts include the merger of scientific and clinical teams into a unified R&D department effective January 1, 2027, while some analysts continue to view competitor Merck as having superior stock performance and diversified growth drivers.

Bristol Myers Squibb Shares Face Scrutiny as Analysts Weigh KarXT Trial Success Against Competitive Pressures
- Preliminary Phase 3 data from the ADEPT program shows that KarXT reduced hallucinations and delusions in patients with psychosis associated with Alzheimer's disease, marking a significant clinical milestone for the pipeline.
- The company reported that growth portfolio revenue rose 12% year over year to $7.7 billion, with eight medicines now annualizing over $1 billion each, demonstrating resilience despite patent expiration headwinds.
- Strategic shifts include the merger of scientific and clinical teams into a unified R&D department effective January 1, 2027, while some analysts continue to view competitor Merck as having superior stock performance and diversified growth drivers.
Six-Month Growth Performance
When is the next earnings date for Bristol Myers Squibb (BMY)?
Bristol-Myers Squibb has not yet announced a confirmed date for its next earnings report. Based on the company's historical reporting pattern, which typically follows a quarterly cycle of approximately three months after the previous release, the next report is expected in early February 2027. This upcoming disclosure will cover financial results for the fourth quarter and full fiscal year 2026. Investors should monitor official communications for the precise scheduling of this anticipated release.
Stock Performance Snapshot
Analyst Rating
Analysts recommend buying Bristol Myers Squibb's stock with a target price of $61.06, indicating potential growth.
Financial Health
Bristol Myers Squibb is generating strong revenue and cash flow, indicating solid financial performance.
Dividend
Bristol Myers Squibb's dividend yield of 3.17% offers a decent income for investors seeking dividends. If you invested $1000 you would be paid $31.70 a year in dividends (based on the last 12 months).
Why You’ll Want to Watch This Stock
Oncology-led revenue engine
BMY’s oncology and haematology drugs drive sales and headline growth, though trial outcomes and competition can cause swings in performance.
Pipeline and R&D programme
A substantial pipeline offers upside if trials succeed, but R&D failures and regulatory delays are common and can affect value.
Cash flow and balance
Established medicines and partnerships support cash flow, yet patent cliffs and post-acquisition debt make balance-sheet management important.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
